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Abstract: Docosahexaenoic acid (DHA) is a structural constituent of membranes specifically in
the central nervous system. Its accumulation in the fetal brain takes place mainly during the last
trimester of pregnancy and continues at very high rates up to the end of the second year of life. Since
the endogenous formation of DHA seems to be relatively low, DHA intake may contribute to optimal
conditions for brain development. We performed a narrative review on research on the associations
between DHA levels and brain development and function throughout the lifespan. Data from cell
and animal studies justify the indication of DHA in relation to brain function for neuronal cell
growth and differentiation as well as in relation to neuronal signaling. Most data from human
studies concern the contribution of DHA to optimal visual acuity development. Accumulating data
indicate that DHA may have effects on the brain in infancy, and recent studies indicate that the
effect of DHA may depend on gender and genotype of genes involved in the endogenous synthesis
of DHA. While DHA levels may affect early development, potential effects are also increasingly
recognized during childhood and adult life, suggesting a role of DHA in cognitive decline and in
relation to major psychiatric disorders.
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1. Introduction
Long chain polyunsaturated fatty acid (LC-PUFA), including docosahexaenoic acid (DHA)
and arachidonic acid (AA), are incorporated into membrane phospholipids and, apart from their
structural role in these membranes, they also act as precursors of autocoid signaling molecules
(e.g., docosanoids) and as potent activators of a number of gene transcription factors (e.g., peroxisome
proliferator activated receptors). The essentiality of n-3 LC-PUFA is generally mainly contributed to
the incorporation of DHA in uniquely high levels in the central nervous system—although DHA is
incorporated in most other tissues where it may also have important functional effects.
Overall, membrane PUFA composition (the principal components of which are linoleic acid
(LA), AA and DHA) seems to be more responsive to DHA in the diet than to intake of LA and
AA [1]. Animal studies have demonstrated that an increase in dietary α-linolenic acid (ALA) is
almost completely reflected in membrane n-3/n-6 PUFA-ratios at LA/ALA intakes of <10, whereas
the dietary balance between ALA and LA has little influence at higher ALA intakes, and a similar
Nutrients 2016, 8, 6; doi:10.3390/nu8010006 www.mdpi.com/journal/nutrients
Nutrients 2016, 8, 6 2 of 17
biphasic response is also seen in diets that contain LC-PUFA [2]. These results show a high sensitivity
of tissue membranes to dietary variations in the PUFA-supply within the normal range, strongly
favoring incorporation of n-3 LC-PUFA over LA and AA. In the case of a dietary deficiency of n-3
PUFA, there is a trend for DHA to be replaced with the nearest n-6 PUFA equivalents, whereas few
changes are seen for the reciprocal lack of dietary of n-6 PUFA [3,4]. Thus, n-3 PUFA seem to be the
main determinant of membrane PUFA composition and unsaturation. Membrane DHA incorporation
in different tissues, e.g., erythrocytes (RBC), has been shown to depend on diet, mainly fish intake and
in infants also breastfeeding, but is also to some extent supported by DHA formed endogenously by
desaturation and elongation of ALA. This conversion is limited by the delta-6 desaturase enzymatic
step, which generally has a low efficiency, but the rate conversion has been shown to be affected by
genetic setup in the fatty acid desaturase (FADS) gene cluster and to vary depending on age and
circulating levels of sex hormones.
The present paper will give an update of the current literature and try to answer the following
questions: (1) Does the high rate of DHA accumulation in the brain have any functional importance?
(2) If yes, is the endogenous synthesis of DHA high enough to support optimal functional levels
of DHA in the brain? Finally, we will also address whether DHA may contribute to normal brain
functioning later in life.
2. Brain DHA Accumulation during Development Depending on Diet
The accumulation of DHA in the brain takes place during the brain growth spurt in the
intrauterine and neonatal period up to two years of age and the high levels of DHA in the brain are
maintained throughout life [5]. Due to the lack of de novo PUFA synthesis, the rate of membrane DHA
incorporation in early life—in the brain as well as in other tissues—depends on maternal transfer,
dietary supply (i.e., breastfeeding) and endogenous LC-PUFA production. The DHA accumulation in
the brain during the third trimester of pregnancy is substantially higher (in % of fatty acids (FA%))
than the overall body deposition rates, whereas brain incorporation of AA is more in line with
that which occurs in other tissues [6]. Fetal LC-PUFAs accumulation occurs mainly during the last
trimester, in which weight increase becomes more rapid and growth is accompanied by a deposition
of fat tissue, which begins around the 30th week of gestation [7]. Fetal fat tissues contain relatively low
levels of DHA and AA [8,9] compared to the large relative amounts of LC-PUFAs that are deposited
in the brain [8,10]. However, the absolute amount of DHA in fetal adipose tissue exceeds that in the
brain [7]. Based on post-mortem studies it has been calculated that whole-body DHA accretion during
the third trimester amounts to around 50 mg/day while the accretion of AA is approximately twice
as high (100 mg/day) [8]. It has been estimated that this fetal LC-PUFA accumulation is supported
by a supply of approximately 50 mg/(kg ˆ day) of n-3 LC-PUFA and 400 mg/(kg ˆ day) of n-6
LC-PUFA [6].
The intrauterine PUFA supply occurs via transfer of non-esterified PUFA mainly derived from
the maternal circulation across the placenta [10,11]. The overall fat concentration in maternal plasma
increases throughout pregnancy [7], and placental fat transport is driven by a concentration gradient
as the fetus has substantially lower fat concentrations [12], including the concentration of DHA
and AA [7,13]. The relative proportion of DHA and AA is, however, consistently higher in circulating
lipids of the neonate [14], whereas the concentrations of LA and ALA differ much less from that in the
maternal blood [15,16], indicating a preferential transfer of LC-PUFA. The exact mechanisms involved
in placental PUFA transfer remain unclear, but is generally considered to involve proteins with some
specificity for LC-PUFA, especially DHA, over PUFAs with shorter chain length [17–19]. Additionally,
DHA has been shown to be incorporated into triacylglycerol in human placental cells, whereas AA is
primarily esterified in phospholipids [20,21], and this differential esterification may contribute to the
preferential transport of DHA and accumulation of AA in the placenta itself. AA has been shown to be
taken up from the maternal blood by the placenta at higher rates than DHA, while DHA accumulates
in the fetal blood stream at a three-fold higher rate than AA [20]. Although other interpretations
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are plausible, the specificity for placental transfer of DHA over AA could be interpreted as a specific
retention of AA on the maternal side possibly for prostaglandin production in relation to the initiation
of delivery. Maternal dietary n-3 LC-PUFA has a slight gestation prolonging effect, which may
be explained by a dampening of the AA-derived eicosanoid response [22], which results in an
increase birth weight and intrauterine LC-PUFA accretion. In infants born preterm the progressive
accumulation of LC-PUFA in fetal tissues is truncated at the end of pregnancy and accumulation is
also strongly limited in growth-retarded fetuses [23].
Post-natal accumulation of LC-PUFA in infant tissues is supported by maternal transfer of
PUFA through breastmilk, and blood levels of LC-PUFA in breast-fed infants remain higher than
maternal levels for some time postnatally [24,25]. In neonate baboons, dietary DHA has been
shown to consistently support greater brain DHA incorporation and maintenance of cortex DHA
concentration, while brain AA is unaffected by dietary supply and decreases with age [26]. Moreover,
brain autopsies from human infants have shown an around 25% higher mean FA% of DHA in
cortical phospholipid of breast-fed (9.7%) compared to age-matched formula-fed infants (7.6%) [27].
The overall percentage of LC-PUFA was maintained in formula-fed infants by a compensatory
increase in the incorporation of n-6 LC-PUFA, which however was incomplete in formula-fed preterm
infants with the lowest concentration of cortical DHA, where an increase in the n-9 series PUFA
was also detected [27]. A second autopsy study also showed an increase in cortex DHA with age
in breast-fed but not in formula-fed infants, whereas the percentage of AA in the brain increased
with age irrespective of diet [28] just as in the infant baboons. Similarly, the RBC DHA content
of breast-fed infants has been found to be higher than that of formula-fed infants [28]. Breastmilk
has been shown to be a main contributor to the DHA content in infant RBC [29], and infant RBC
DHA has been shown to be associated with maternal n-3 LC-PUFA intake and RBC DHA status
during lactation [30]. RBC DHA decrease after infancy as complementary feeding usually supplies
less DHA [31]. The intake of n-3 LC-PUFA has been shown to be low in a number of studies in
children [32] and European children have been shown to have whole blood n-3 LC-PUFA levels
consistently below 2.5 FA% between 3 and 8 years of age [33].
The phenomenon of increasing LC-PUFA in fetal and infant blood and tissues relative to that of
their mother has been described as “bio-magnification” [34], but could also be interpreted as a natural
consequence of a dual liver system i.e., the combined PUFA metabolism and conversion of LA and
ALA to AA and DHA in both the mother and the fetus/infant. Both term and preterm infants have
been shown to convert stable isotope labeled LA and ALA to AA and DHA, respectively [35–37], and
the synthesis has been shown to decrease with post-conceptional age [38]. The desaturase capacity
has been estimated to be in the order of 40 mg/(kg ˆ day) of AA and 13 mg/(kg ˆ day) of DHA in
neonates born in the 32nd week of gestation, but to decrease to around 14 and 3 mg/(kg ˆ day) at
1 month past expected term [39]. This synthetic rate may still provide a substantial contribution to
fulfill infant needs, which, based on maintenance of plasma DHA homeostasis, have been estimated
to be around 5 mg/(kg ˆ day) of DHA [40]. However, this does not exclude that exogenous sources
of DHA are needed in the diet to fulfill the requirements of the growing infant.
3. Effects of FADS Polymorphisms on LC-PUFA Levels
Overall, data suggest that n-6 PUFAs in breastmilk, plasma and RBC membranes across
all ages are more affected by single nucleotide polymorphisms (SNPs) in the FADS gene cluster
than n-3 PUFAs, typically with an increase in LA and a decrease in AA levels in minor allele
carriers [29,41–45]. Minor allele homozygotes of various FADS SNPs have also been found to
have lower blood (RBC and plasma) levels of AA and higher levels of LA and ALA during
pregnancy [41,42]. FADS polymorphisms have been estimated to explain as much as 29% of the
variation in serum AA contents in adults, in whom serum DHA concentrations are determined
primarily by the dietary supply of preformed DHA [43]. Colostrum AA and DHA levels have
been found to be decreased in minor allele carriers of a number of FADS SNPs [46], but studies in
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mature breastmilk have shown that the concentration of AA is influenced to a larger extent than
that of DHA [41,47,48]. Findings in plasma from both mothers and neonates have shown strong
inverse associations between the minor allele for two FADS SNPs and the concentrations of DHA and
eicosapentaenoic acid (EPA) as well as AA in the newborn infants, thus confirming that synthesis of
DHA provides a relevant contribution to status [49]. Curiously, a study of 2000 cord blood samples
found that minor allele FADS SNPs in the mother gave rise to increased levels of n-6 PUFA before
the delta-5 desaturation step (LA and di-homo-γ-linoleic acid), whereas minor allele SNPs in the
child resulted in decreased levels of AA and other n-6 LC-PUFA beyond this point in the metabolic
pathway [50]. More data on the biochemical effects of FADS polymorphisms are needed to derive
a biologically plausible interpretation of their potential functional effects. Furthermore, both AA
and DHA needs to be considered together since apart from the main determinants of their levels,
either endogenous or exogenous, their balance may be critical for the functional outcomes in infancy
and beyond.
We have recently found that some FADS polymorphisms may substantially contribute to RBC
DHA levels in late infancy (to the same extent as breastfeeding) [29]. Some SNP minor alleles (rs1535
and rs3834458) were even found to dose-dependently up-regulate DHA status [29], whereas minor
alleles of all the investigated SNPs lowered AA in a consistent way [51]. Interestingly, identical
analyses did not reveal any effect of these SNPs on RBC DHA at 3 years of age [29], which could
be explained by increased residual variation in the model due to a more diverse fish intake or could
be interpreted as a decline in the endogenous DHA biosynthesis, consistent with other findings [39].
Furthermore, a longitudinal study of serum phospholipid fatty acid composition at 2 and 6 years of
age in 331 children found higher tracking in n-3 LC-PUFA levels in children who were major allele
carriers [52]. Instead tracking of n-6 LC-PUFA was lower in major allele homozygotes of various
FADS SNPs compared to tracking in carriers of at least one minor allele [52]. More longitudinal
outcome data may suggest plausible biological interpretations. However, although DHA may mainly
be determined by variation in intake, mainly of preformed DHA, the genetic patterns also appear to
be of relevance for tissue DHA levels in the perinatal phases, although probably less later in life as
the rate of endogenous synthesis declines, thus increasing the importance of exogenous DHA.
4. Dietary DHA and Postnatal Development
The majority of the randomized controlled trials investigating the effect of dietary LC-PUFA
supplementation in term infants have added both DHA and AA, and only few have investigated the
effect of varying DHA intakes at a constant intake of AA. With respect to the functional effects of
LC-PUFA supplementation in infancy, the most accepted developmental effect is an increased rate of
visual acuity development [53]. This effect seems to be explained solely by DHA, as a meta-regression
analysis found that variability in the effects on visual acuity between studies was explained by the
dose of DHA [54]. However, little is known regarding the persistency of this effect on vision and the
potential effects that this early visual deficit may have on cognitive development.
Overall, meta-analyses of the randomized controlled trials that have investigated the effect
of LC-PUFA supplementation on neurodevelopmental outcomes throughout the first two years of
life have not shown any clear benefit of LC-PUFA addition to infant formula on development of
term or preterm infants [55–57]. However, a meta-analysis that combined all LC-PUFA formula
supplementation trials in both term and preterm infants found a trend for an effect on the Bayley scale
Mental Developmental Index at around 12 months of age, which were not affected by the maturity of
the infant at birth [57]. This meta-analysis did not find any effect of LC-PUFA dose, although there
was a trend towards an effect of the DHA dose, but no such trend for AA [57]. The studies that have
supplemented the infants with DHA indirectly via n-3 LC-PUFA supplementation of their pregnant
or lactating mothers, generally provide a more clean way to study effects of the early DHA supply
as this has little effect on the AA supply to the infant. A meta-analysis of randomized trials that
supplemented lactating mothers with n-3 LC-PUFA showed that infants of supplemented mothers
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had larger heads at 2 years of age [58]. Furthermore, the meta-analyses looking at the developmental
effects of maternal n-3 LC-PUFA supplements in pregnancy and lactation have suggested some effects
on neurodevelopment based on a few studies [58,59]. However, at the current stage, this does
not provide any definite proof that an increase in the early DHA supply improves the mental
development of infants.
So far, few studies have shown that the effect of perinatal n-3 LC-PUFA supplementation may be
affected by the gender of the child. In two large investigations, the DINO and DOMInO trials [60,61],
an increased early DHA supply was associated with different effects on cognitive outcomes in girls
and boys. A gender-treatment interaction on cognitive outcomes was also observed in a small
Danish trial of maternal fish oil supplementation during lactation [62], although no clear effects were
observed when the children were followed up at 7 years of age [63]. The different effects of increased
DHA supply on various outcomes in girls and boys all appear to counteract the normally observed
gender differences in behavior. It is not clear if these effects should be interpreted as beneficial in one
gender and adverse in the other or if it is due to some other effect of DHA that diminish the cultural
gender differences which we have come to perceive as normal biological differences. Interestingly,
in the Danish maternal fish oil supplementation trial treatment-gender interactions were found also
on blood pressure at 7 years of age [64]. Blood pressure is not normally defined as cognitive outcome,
but is nevertheless affected by the central nervous system in response to anxiety. As was the case
with cognitive outcomes, boys and girls in the fish oil group were found to have comparable diastolic
and mean arterial blood pressures, whereas girls had higher blood pressures than boys in the control
group [64]. The intervention was also found to level out gender differences on energy intake and
physical activity at 7 years of age [64]. Accordingly, these results indicate that early DHA intake
could also have long-term health consequences, which might be mediated effects in the brain and
lifestyle choices.
Many of the available studies on the effects of maternal or, more commonly, infant n-3 LC-PUFA
supplementations on neurodevelopmental outcome during infancy have several limitations, which
become more and more evident as our knowledge on the physiology of LC-PUFA, and DHA in
particular, progresses. The vast majority of the studies, whether on cognition of other functional
outcomes or if they provide the supplement during pregnancy, lactation or to the infant in various
types of formula, show a great heterogeneity with respect to LC-PUFA sources, doses of DHA
(and AA) and durations of interventions. It should be noted that the methodologies for primary
outcome assessment as well as age of effect examination differed between trials, and the effects in the
first few years of life and potential long-term effects may be quite different. For outcomes such as
neurological and cognitive development, there may be a necessity to use different tests at different
ages to accommodate changes in age and maturity level. However, many trials have investigated
effects on numerous outcome measures, which are often internally inconsistent, or show no apparent
pattern over time. In addition, studies often have low power in terms of the number of participants
and sometimes also high rates of dropouts as well as lack of intention-to-treat analysis and a sufficient
description of allocation concealment. Although baseline demographic characteristics are constantly
reported, often baseline n-3 PUFA intake or status is not included in the characterization. This
omission is critical for the interpretation, since baseline n-3 PUFA status will likely affects the response
to changes in n-3 PUFA intake—both with respect to acute and persistent functional effect. Finally,
as mentioned above, the effects of early n-3 LC-PUFA supply may vary in boys and girls, and this is
not taken into account in the older studies. The emerging knowledge indicates that it is critical to take
these aspects into account and that the variation in these aspects complicate attempts to combine data
in meta-analyses to achieve conclusions with respect to the functional consequences of the addition
of LC-PUFA, even beyond the single, specific effects of DHA.
Nutrients 2016, 8, 6 6 of 17
5. Effects of FADS Polymorphisms on Cognition and Neurobehavioral Outcomes
Current knowledge about the functional effects of FADS polymorphism is limited and although
the most clear effect on PUFA metabolism as mentioned is a decrease in AA production, functional
associations with FADS genotype cannot be interpreted as a consequence of a reduction in AA.
The influence of FADS polymorphisms on LC-PUFA status—and specifically the observed variations
between specific SNPs and specific LC-PUFA over time—introduces new variables to be considered
in the evaluation of the effects of FADS genotype on development and health of young children.
Several studies have showed that infant FADS genotype, examined by use of different
individual SNPs, modifies the effect of breastfeeding on IQ-like neurodevelopmental outcomes in
childhood [46,65,66], while other studies did not find any significant interaction [67,68] (Figure 1).Nutrients 2015, 7, page–page 
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Figure  1.  Results  from  studies  examining  the  potential  modifying  effect  of  single  nucleotide 
polymorphisms  in  the  fatty acid desaturase gene  cluster on  the effect of breastfeeding on  IQ‐like 
neurodevelopmental outcomes in children. The figure is based on data from [46,65–68] and gives the 
average IQ in the SNP×feeding groups (breast‐fed in black and formula‐fed in light gray). The grey 
stippled line is the reference line for mean normal IQ. 
As expected, based on the observed differences between breast‐fed and formula‐fed infants, all 
the studies have higher scores in breast‐fed compared to formula‐fed major allele carriers, but with 
no apparent differences between homozygotes and heterozygotes, which might be expected based 
on the additive effects of number of major alleles that is expected according to the observed effects 
on  LC‐PUFA.  Thus,  an  interaction  is  dependent  on  a  different  pattern  among  the minor  allele 
homozygotes (or the minor allele carriers in the Spanish study in which these were pooled with the 
heterozygotes). In the studies that found an interaction this is based on an equal “IQ” in breast‐fed 
and formula‐fed in the two cohorts in the Caspi study [66] and the two Spanish cohorts [46], whereas 
the largest of the studies found an even bigger difference between breast‐fed and formula‐fed among 
the minor allele homozygotes [65]. However, in all of the studies there were only few formula‐fed 
minor allele carriers, and thus the largest variation in this group was likely skewed because of the 
scores  of  few  children were  at  a  high  risk  of  chance  effects.  The  studies  differ with  respect  to 
breastfeeding frequency as well as the definition of breastfeeding, which in the large UK study was 
defined as >1 months [65] and ever having been breast‐fed in the Dutch study [67], but was not clearly 
defined  in other studies  [46,66]. The Australian study  tried  to examine  the effect of breastfeeding 
duration (not apparent in the figure in which we have pooled all the breast‐fed groups), but they did 
not have the power to judge this due to a lack of a statistical (although visual indicated) dose‐response 
between duration of breastfeeding and IQ [68]. The Dutch study found that the effect appeared to 
vary—although  not  significantly—between  different  cognitive  functions  and  testing  ages  [67]. 
Furthermore, given the variation in the year of birth of the subjects in the studies, it is also reasonable 
to  assume  that  there  could have been differences  in  the PUFA  composition of  the  formulas  and 
presumably also in the maternal fish intake, and lifestyle in general, and thus in the DHA content of 
the breastmilk of the study populations. Little is known regarding interactions between the FADS 
polymorphisms and intake of AA and DHA from breastmilk and infant formula or the dietary ratio 
between the precursors, LA and ALA, but it is reasonable to suspect that this might have an influence 
on  the  functional  response.  Due  to  the  increasing  availability  of  micro‐invasive  methods  for 
determination of blood fatty acid status, future Mendelian randomization studies should now be able 
to study effects of these potential sources of heterogeneity. 
Additionally,  the  studies on  interactions between breastfeeding and  IQ used different FADS 
SNPs (mainly rs174575, rs1535 and rs174468), but, as  indicated by the aforementioned study from 
Harsløf and coworkers, they may not all down‐regulate the endogenous DHA synthesis in the infants 
[29]. This  could  contribute  to  the observed variable  associations,  and  it  is  important  to  consider 
potential disequilibrium with other SNPs  in  the  interpretation of  the  results  from  the FADS SNP 
studies.  Interestingly,  Steer  et  al.  reported  opposing  effects  of  rs174574  and  rs3834458  in  the 
modulation of  the association between breastfeeding and  IQ  [69]. Opposing effects of  rs1535 and 
rs174448 have also been observed in problem solving and communication skills assessed by the Ages 
and Stages Questionnaire (ASQ) in a recent study among 3 year‐olds [51]. None of the FADS SNP‐
Figure 1. Results from studies examining the potential modifying effect of single nucleotide
polymorphisms in the fatty acid desaturase gene cluster on the effect of breastfeeding on IQ-like
neurodevelopmental outcomes in children. The figure is based on data from [46,65–68] and gives the
average IQ in the SNPˆfeeding groups (breast-fed in black and formula-fed in light gray). The grey
stippled line is the reference line for mean normal IQ.
As expected, based on the observed differences between breast-fed and formula-fed infants, all
the studies have higher scores in breast-fed compared to formula-fed major allele carriers, but with no
apparent differences between homozygotes and heterozygotes, which might be expected based on
the additive effects of number of major alleles that is expected according to the observed effects
on LC-PUFA. Thus, an interaction is dependent on a different pattern among the minor allele
homozygotes (or the minor allele carriers in the Spanish stu y in hich these were pooled with the
heterozygot ). In the studies that found an interaction this is bas d on an equal “IQ” in breast-fed
and formula-fed in t e two cohorts in the Caspi study [66] and the two Spanish cohorts [46], whereas
the largest of the studies found an even bigger difference between breast-fed and formula-fed among
the minor allele homozygotes [65]. However, in all of the studies there were only few formula-fed
minor allele carriers, and thus the largest variation in this group was likely skewed because of
the scores of few children were at a high risk of chance effects. The studies differ with respect to
breastfeeding frequency as well as the definition of breastfeeding, which in the large UK study was
defined as >1 months [65] and ever having been breast-fed in the Dutch study [67], but was not clearly
defined in other studies [46,66]. The Australian study tried to examine the effect of breastfeeding
duration (not appare t in the figure in which we have po led all the brea t-fe groups), but they did
not have the p wer to judge this due to a lack f a statistical (although vi ual indicated) do e-response
between duration of breastfeeding and IQ [68]. The Dutch study found that the effect appeared
to vary—although not significantly—between different cognitive functions and testing ages [67].
Furthermore, given the variation in the year of birth of the subjects in the studies, it is also reasonable
to assume that there could have been differences in the PUFA composition of the formulas and
presumably also in the maternal fish intake, and lifestyle in general, and thus in the DHA content
of the breastmilk of the study populations. Little is known regarding interactions between the FADS
polymorphisms and intake of AA and DHA from breastmilk and infant formula or the dietary
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ratio between the precursors, LA and ALA, but it is reasonable to suspect that this might have an
influence on the functional response. Due to the increasing availability of micro-invasive methods
for determination of blood fatty acid status, future Mendelian randomization studies should now be
able to study effects of these potential sources of heterogeneity.
Additionally, the studies on interactions between breastfeeding and IQ used different FADS
SNPs (mainly rs174575, rs1535 and rs174468), but, as indicated by the aforementioned study from
Harsløf and coworkers, they may not all down-regulate the endogenous DHA synthesis in the
infants [29]. This could contribute to the observed variable associations, and it is important to
consider potential disequilibrium with other SNPs in the interpretation of the results from the FADS
SNP studies. Interestingly, Steer et al. reported opposing effects of rs174574 and rs3834458 in the
modulation of the association between breastfeeding and IQ [69]. Opposing effects of rs1535 and
rs174448 have also been observed in problem solving and communication skills assessed by the
Ages and Stages Questionnaire (ASQ) in a recent study among 3 year-olds [51]. None of the FADS
SNP-breastfeeding interaction studies have considered whether the effect might differ between boys
and girls. As in the DINO trials [60], the Mendelian randomization of FADS SNPs versus 3-year ASQ
outcomes found that the effect of DHA increasing SNPs appeared to be negative in girls and positive
in boys [51]. Due to the previously mentioned opposing effects of these SNPs on DHA in early life
and the lack of opposing effects on AA plus the lack of association between FADS SNPs and DHA
status at 3 years of age, these results might be interpreted as proof of a programming effect specifically
of early DHA dietary intakes. However, the lack of effect of the FADS SNPs on DHA status later in
life could be due to a blurring effect of a more diverse dietary intake of DHA from fish. Therefore,
it is not possible to rule out that DHA supply contrary to the current hypothesis of an early window
of vulnerability might have an effect on brain function at all stages of life.
6. Neurobehavioural Outcomes in Older Children
Brain DHA accretion continues into childhood, and although the accretion rate declines,
the incorporation of DHA is still high at least during the preschool years. Once high levels of DHA
are achieved in the brain these are maintained during later life, and this presumably also depends
on an optimal dietary supply, as dietary intake of DHA from fish in adults has been shown to be
the dominant determinant of DHA levels in various lipid pools [70]. However, to our knowledge no
studies have examined the dietary requirements in order to achieve optimal brain DHA maintenance.
Few studies have investigated the effect of FADS SNPs or n-3 LC-PUFA supplementation on cognitive
development, emotions and behavior in toddlers and later in childhood or even in healthy adults.
A single study pooling data from three trials that randomized to LC-PUFA formulas
immediately after birth or after breastfeeding for 6 weeks or 4–6 months, respectively and continued
supplementation throughout the first year of life, found significant beneficial effects on problem
solving at 9 months of age only in the two studies that started intervention early [71]. However,
one study that examined the effects of DHA-enriched baby food also found an apparent improvement
of cognitive outcomes [72]. Furthermore, a trial that provided a teaspoonful of cod liver oil (free of
vitamin A and D) from 9 to 12 month of age found an increase in voluntary attention in a free play
test after the intervention, especially in boys, compared with un-supplemented children [73].
Results from studies in schoolchildren in low-income countries have shown relatively
convincing cognitive effects of fish oil supplementation. The effects have been shown to be stronger
in children with low socioeconomic status or malnutrition-related health problems and a low
consumption of fish and very little n-3 PUFA [74,75]. However, no overall cognitive effects were
found after fish oil supplementation of 6–11 year-old South African children with poor iron and n-3
LC-PUFA status [75], but paradoxically an adverse effect of fish oil was observed on memory mainly
in girls and specifically those with iron deficiency anemia. Little research has been performed on
the effects of n-3 LC-PUFA on brain functions in school-aged children from high-income countries.
One functional magnetic resonance imaging study showed that DHA supplementation was
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associated with increased activation of the prefrontal cortex and better reaction time during sustained
attention in healthy 8–10 year-old boys [76]. In a cross-over intervention trial with more than
800 schoolchildren we have recently found that healthy school meals rich in fish improve school
performance [77]. Some observational studies have also observed a positive association between
n-3 LC-PUFA intake and cognitive performance. A study of 4000 American children found that the
association between n-3 LC-PUFA intake and cognitive performance was stronger in girls than in
boys [78]—again, an example of gender-related nutrition. Four randomized trials have supplied
schoolchildren from high-income countries specifically with n-3 LC-PUFA [79–82]. Three of these
studies found some beneficial effects on cognition or school performance of 0.4–1 g/day of n-3
LC-PUFA, while the study that did not find any effect supplied only around 0.2 g/day [79].
This dose-response effect is however not always consistent, as a three-armed study in 90 British
10–12 year-old children found a beneficial effect of 0.4 g/day of DHA on word recognition, but poorer
performance in children who had 1 g/day [80].
In the last mentioned study, all the DHA supplemented children had a more relaxed mood
compared to controls [80], which is consistent with another trial that found an apparent effect on
mood, i.e., a reduction in impulsivity and anti-social behavior, in 450 healthy 8–10 year-old children
supplemented with fish oil versus olive oil [81]. Similar behavioral effects were also observed in
one of the South African studies, which showed a decrease in physical activity during school hours,
less oppositional behavior, inattention and lower scores on a rating scale of traits of attention-deficit
hyperactivity disorder (ADHD) after fish oil supplementation [82]. Comparable behavioral effects
have also been indicated, although not firmly proven, in children with ADHD [83] and in addition,
one study has found an association between FADS SNPs and the development of ADHD, specifically
in the context of prenatal alcohol exposure [84]. It is difficult to draw any firm conclusions
based on the results of these trials and observational studies in schoolchildren due to differences
in dose, duration and most of all the tested outcomes. Furthermore, the studies on behavioral
conditions may be biased due to methodological flaws such as limited sample size and the large
number of neurological tests that were performed in most of the studies (out of which only a few
showed significant effects). More well-conducted studies, adjusted for multiple test administrations,
are therefore needed in order to provide more convincing evidence for an effect of n-3 LC-PUFA
intake on cognitive, behavioral and emotional effects in children.
So far, the effect of gender has not been given much attention in intervention trials with n-3
LC-PUFA in preschool and school-aged children. However, as was the case in the studies on the
effects of DHA in the perinatal period, a gender-treatment effect has been observed on mean arterial
blood pressure after fish oil supplementation from 9 to 18 month of age in healthy Danish infants,
which just as in the previously mentioned maternal fish oil supplementation study was mostly
affected in boys [85]. In this case, blood pressure was reduced in the boys, which however was
still counteracting the observed gender difference in the control group, resulting in an almost similar
mean arterial blood pressure in the girls and boys of the fish oil supplemented group [85]. A similar
gender-equalizing effect was observed on the systolic blood pressure later in infancy in a study
that compared fish oil versus no supplement during the complementary feeding period [86]. In that
study, the observed changes in systolic blood pressure were found to correlate with the previously
mentioned changes in free play attention [73], which could indicate a common emotional component.
Furthermore, a recent randomized controlled cross-over trial in young adults also observed a
gender-specific effect of fish oil supplementation on the sensation of appetite that abolished gender
differences observed after a three week intervention in the soy oil control period [87].
7. Neurobehavioural Outcomes beyond Childhood
Only a few studies have examined if fish oil supplementation can affect brain functions in
healthy young adults, but some studies indicate that DHA may be important for cognition and
behavior during late adulthood. DHA supplementation improved memory in healthy, young adults
Nutrients 2016, 8, 6 9 of 17
whose habitual diets were low in DHA, and the response was still modulated by sex [88] suggesting
consistence with the effects found in late infancy with the achievement of gross motor milestones [89].
An observational study conducted in 6158 individuals of >65 years found that high fish consumption,
but not dietary n-3 LC-PUFA intake, had a protective effect on cognitive decline [90,91]. A systematic
review and meta-analysis from 2006 gathered all available evidence from observational, preclinical
and clinical studies to assess the effects of n-3 LC-PUFA on cognitive protection [92]. Four of the trials
have shown a protective effect of n-3 LC-PUFA only among those with mild cognitive impairment
conditions [93]. In another trial with 485 subjects with mild memory complaints, an improvement
of memory was demonstrated after 0.9 g/day of DHA for 24 weeks [94]. A recent meta-analysis of
all randomized trials that have investigated the effect of fish oil on cognitive decline also indicated a
potential beneficial effect, but only in trials that had supplied >1 g/day of DHA in subjects who at
the beginning of the trail exhibited some signs of cognitive decline [90]. There are nine separate
observational studies that have suggest a possible link between increased fish consumption and
reduced risk of Alzheimer’s disease [95,96]. Furthermore, analysis of human cadaver brains has
shown that people with Alzheimer disease have less DHA in their frontal lobe and hippocampus
compared with unaffected individuals [97]. In addition, studies in mice provide support for the
protective role of n-3 LC-PUFA, showing that a dietary intake of DHA induces an increase in DHA
levels in the hippocampus with subsequent improvement of memory performances [98].
DHA has also been suggested to be effective in major psychiatric disorders. Most of the
conducted studies have used n-3 LC-PUFA levels in RBC membranes as a measure of exposure,
due to the objectivity of this measure and their high correlation with habitual dietary intake [99] in
addition to their presumed reflection of brain LC-PUFA levels. Such studies have shown a significant
correlation between DHA deficits and schizophrenia [100]. Life style in schizophrenia is characterized
by heavy smoking, drinking, high-caloric diets, low physical activity and use of drugs that cause
oxidative stress in the body. However, a recent study found no reduction of either DHA or AA in large
groups of un-medicated Indian and Malaysian patients suffering from schizophrenia [101]. There is a
tendency for RBC membrane levels of DHA and AA to diminish during storage, and this may happen
abnormally rapidly in schizophrenia [102], possibly because of an increased oxidative stress [103].
Interestingly, several studies reported a better outcome in psychotic patients supplemented with n-3
LC-PUFA, either EPA or DHA [104].
Accumulating evidence also suggests that n-3 LC-PUFA supplementation may be efficacious
for the treatment of positive and negative symptoms in patients with schizophrenia or at ultra-high
risk for psychosis [105]. There is also some evidence that n-3 LC-PUFA may be relevant in
relation to the pathophysiology of depression [106]. Cross-national studies indicate that higher
intake of fish/seafood is correlated with lower lifetime prevalence rates of unipolar and bipolar
depression [107]. In fact, depression may present with an increased production of pro-inflammatory
cytokines and elevations in plasma homocysteine levels [108], and n-3 LC-PUFA have in randomized
controlled trials been shown to be able to reduce both [109]. Thus, it can be speculated that
n-3 PUFAs produce a positive effect on mood, partly because of the high brain content of DHA
and its involvement in neurogenesis and neuroplasticity and partly due to their anti-inflammatory
properties [110] as well as their effect on carbon metabolism, which is known to be of importance in
relation to the metabolism of mono-aminergic neurotransmitters [111]. Some epidemiological studies
have in the same way found that lower n-3 LC-PUFA intake is linked to an increased risk for emerging
depressive symptoms [112]. Therefore, higher habitual dietary n-3 LC-PUFA intake may be protective
against mood swings or even ultimately prevent mood dysregulation [113]. There is however a need
for large well-performed randomized controlled trials in this area in order to confirm such effects.
8. Conclusions
The effects of DHA on brain and cognitive development have been extensively investigated in
the last years. Its functional effects have been progressively, but not entirely, separated from those
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of AA. Clinical trials on maternal and infant dietary intakes are not entirely clear and consistent,
but seem to indicate a complex interaction between the genotype pattern of FADS, gender, dietary
intakes and lifestyle. For these reasons it is difficult to disentangle the effects of dietary DHA from
the results of the randomized supplementation trials. In future studies an appropriate sample size
should be calculated in order to adjust for the different variables. Mendelian trials provide a new tool
to investigate the effects of LC-PUFA on cognitive development, but the interpretation of results from
such trials requires an improved understanding of the biochemical effects of individual FADS SNPs
and also needs to consider the potential differences between boys and girls.
Thus, our two questions, (1) Does the high rate of DHA accumulation in the brain have any
functional importance? (2) If yes, is the endogenous synthesis of DHA high enough to support
optimal functional levels of DHA in the brain? Regarding the first, there is clear evidence that DHA
contributes to the visual development of infants, as also concluded by EFSA [53], but the associations
with cognitive development are still not clearly interpreted [114,115], and one of the main problems
could be that the effects differ between boys and girls, which needs to be considered in future
trials. Due to the proposed early window of vulnerability, so far few studies have focused on the
potential effects of n-3 LC-PUFA intake on cognitive and behavioral outcomes in children and young
adults, but available studies indicate that the hypothesis might be worth challenging. Finally, there
is preliminary evidence that DHA may ameliorate cognitive decline and affect behavioral symptoms
in major neuropsychiatric disorders such as dementia, schizophrenia and depression. There is an
extremely poor availability of trials on the effect of DHA supplementations that have investigated the
changes in the fatty acid status as a function of the FADS polymorphisms. Most evidence indicates
that the DHA accumulation is mainly affected by dietary intake, specifically of preformed DHA.
However new studies indicate that the genetic make-up in the FADS gene cluster may contribute
substantially to the current understanding, but that the effects may be SNP-specific and may even
vary with age, or at least are most evident in the perinatal period, where the endogenous synthesis
of LC-PUFA is upregulated and diet may be more easily controlled for, especially during lactation
(or formula feeding).
Author Contribution: All the Authors contributed significantly to the paper. Lotte Lauritzen drafted the
two sections about FADS and Neurobehavioural Outcomes in Older Children with assistance from Laurine BS
Harsløf, the section on Dietary DHA and Postnatal Development and the background section on Brain DHA
Accumulation during Development Depending on Diet was drafted by Lotte Lauritzen and Carlo Agostoni, and
the section on Neurobehavioural Outcomes beyond Childhood was drafted by Paolo Brambilla and Valentina
Ciappolino. Alessandra Mazzocchi and Valentina Ciappolino performed the literature search, commented on
the manuscript, proof read and ordered the references.
Conflicts of Interest: The authors declare no conflict of interest. PB was partially supported by grants from the
Italian Ministry of Health (GR-2010-2317873).
Abbreviations
AA: Arachidonic acid;
ADHD: Attention-Deficit Hyperactivity Disorder;
ALA: α-linolenic acid;
DHA: Docosahexaenoic acid;
EPA: Eicosapentaenoic acid;
FA%: % of the fatty acids;
FADS: Fatty acid desaturase gene;
LA: Linoleic acid;
LC-PUFA: Long chain PUFA;
PUFA: Polyunsaturated fatty acid;
RBC: Erythrocyte;
SNP: Single nucleotide polymorphism
Nutrients 2016, 8, 6 11 of 17
References
1. Vlaardingerbroek, H.; Hornstra, G.; de Koning, T.J.; Smeitink, J.A.; Bakker, H.D.; de Klerk, H.B.;
Rubio-Gozalbo, M.E. Essential polyunsaturated fatty acids in plasma and erythrocytes of children with
inborn errors of amino acid metabolism. Mol. Genet. Metab. 2006, 88, 159–165. [CrossRef] [PubMed]
2. Abbott, S.K.; Else, P.L.; Atkins, T.A.; Hulbert, A.J. Fatty acid composition of membrane bilayers: Importance
of diet polyunsaturated fat balance. Biochim. Biophys. Acta 2012, 1818, 1309–1317. [CrossRef] [PubMed]
3. Neuringer, M.; Connor, W.E.; Lin, D.S.; Barstad, L.; Luck, S. Biochemical and functional effects of prenatal
and postnatal omega 3 fatty acid deficiency on retina and brain in rhesus monkeys. Proc. Natl. Acad.
Sci. USA 1986, 83, 4021–4025. [CrossRef] [PubMed]
4. Carrie, I.; Clement, M.; de Javel, D.; Frances, H.; Bourre, J.M. Specific phospholipid fatty acid composition
of brain regions in mice: Effects of n-3 polyunsaturated fatty acid deficiency and phospholipid
supplementation. J. Lipid Res. 2000, 41, 465–472. [PubMed]
5. Carver, J.D.; Benford, V.J.; Han, B.; Cantor, A.B. The relationship between age and the fatty acid composition
of cerebral cortex and erythrocytes in human subjects. Brain Res. Bull. 2001, 56, 79–85. [CrossRef]
6. Cetin, I.; Alvino, G.; Cardellicchio, M. Long chain fatty acids and dietary fats in fetal nutrition. J. Physiol.
2009, 587, 3441–3451. [CrossRef] [PubMed]
7. Haggarty, P. Effect of placental function on fatty acid requirements during pregnancy. Eur. J. Clin. Nutr.
2004, 58, 1559–1570. [CrossRef] [PubMed]
8. Kuipers, R.S.; Luxwolda, M.F.; Offringa, P.J.; Boersma, E.R.; Dijck-Brouwer, D.A.J.; Muskiet, F.A.J.
Fetal intrauterine whole body linoleic, arachidonic and docosahexaenoic acid contents and accretion rates.
Prostaglandins Leukot. Essent. Fat. Acids 2012, 86, 13–20. [CrossRef] [PubMed]
9. Kuipers, R.S.; Luxwolda, M.F.; Offringa, P.J.; Boersma, E.R.; Dijck-Brouwer, D.A.J.; Muskiet, F.A.J.
Gestational age dependent changes of the fetal brain, liver and adipose tissue fatty acid compositions in a
population with high fish intakes. Prostaglandins Leukot. Essent. Fat. Acids 2012, 86, 189–199. [CrossRef]
[PubMed]
10. Clandinin, M.T.; Chappell, J.E.; Leong, S.; Heim, T.; Swyer, P.R.; Chance, G.W. Intrauterine fatty acid
accretion rates in human brain: Implications for fatty acid requirements. Early Hum. Dev. 1980, 4, 121–129.
[CrossRef]
11. Herrera, E. Implications of dietary fatty acids during pregnancy on placental, fetal and postnatal
development—A review. Placenta 2002, 23, S9–S19. [CrossRef] [PubMed]
12. Campbell, F.M.; Gordon, M.J.; Dutta-Roy, A.K. Placental membrane fatty acid-binding protein
preferentially binds arachidonic and docosahexaenoic acids. Life Sci. 1998, 63, 235–240. [CrossRef]
13. Haggarty, P. Fatty acid supply to the human fetus. Annu. Rev. Nutr. 2010, 30, 237–255. [CrossRef] [PubMed]
14. Montes, R.; Chisaguano, A.M.; Castellote, A.I.; Morales, E.; Sunyer, J.; Lopez-Sabater, M.C. Fatty acid
composition of maternal and umbilical cord plasma and early childhood atopic eczema in a Spanish cohort.
Eur. J. Clin. Nutr. 2013, 67, 658–663. [CrossRef] [PubMed]
15. Agostoni, C.; Galli, C.; Riva, E.; Rise, P.; Colombo, C.; Giovannini, M.; Marangoni, F. Whole blood fatty
acid composition at birth: From the maternal compartment to the infant. Clin. Nutr. 2011, 30, 503–505.
[CrossRef] [PubMed]
16. Oliveira, O.R.C.; Santana, M.G.; Santos, F.S.; Conceicao, F.D.; Sardinha, F.L.C.; Veiga, G.V.;
do Carmo, M.G.T. Composition of fatty acids in the maternal and umbilical cord plasma of adolescent and
adult mothers: Relationship with anthropometric parameters of newborn. Lipids Health Dis. 2012, 11, 157.
[CrossRef] [PubMed]
17. Gil-Sanchez, A.; Larque, E.; Demmelmair, H.; Acien, M.I.; Faber, F.L.; Parrilla, J.J.; Koletzko, B.
Maternal-fetal in vivo transfer of (13C)docosahexaenoic and other fatty acids across the human placenta
12 h after maternal oral intake. Am. J. Clin. Nutr. 2010, 92, 115–122. [CrossRef] [PubMed]
18. Campbell, F.M.; Dutta-Roy, A.K. Plasma-membrane fatty acid binding protein (FABPpm) is exclusively
located in the maternal facing membranes of the human placenta. FEBS Lett. 1995, 375, 227–230. [CrossRef]
19. Dutta-Roy, A.K. Transfer of long-chain polyunsaturated fatty acids across the human placenta.
Prenat. Neonat. Med. 1997, 2, 101–107.
Nutrients 2016, 8, 6 12 of 17
20. Crabtree, J.T.; Gordon, M.J.; Campbell, F.M.; Dutta-Roy, A.K. Differential distribution and metabolism
of arachidonic acid and docosahexaenoic acid by human placental choriocarcinoma (BeWo) cells.
Mol. Cell. Biochem. 1998, 185, 191–198. [CrossRef] [PubMed]
21. Campbell, F.M.; Clohessy, A.M.; Gordon, M.J.; Page, K.R.; Dutta-Roy, A.K. Uptake of long chain fatty acids
by human placental choriocarcinoma (BeWo) cells: Role of plasma membrane fatty acid binding protein.
J. Lipid Res. 1997, 38, 2558–2568. [PubMed]
22. Allen, K.G.D.; Harris, M.A. The role of n-3 fatty acids in gestation and parturition. Exp. Biol. Med. 2001,
226, 498–506.
23. Cetin, I.; Giovannini, N.; Alvino, G.; Agostoni, C.; Riva, E.; Giovannini, M.; Pardi, G. Intrauterine growth
restriction is associated with changes in polyunsaturated fatty acid fetal-maternal relationships. Pediatr. Res.
2002, 52, 750–755. [CrossRef] [PubMed]
24. Jørgensen, M.H.; Nielsen, P.K.; Michaelsen, K.F.; Lund, P.; Lauritzen, L. The composition of polyunsaturated
fatty acids in erythrocytes of lactating mothers and their infants. Mater. Child Nutr. 2006, 2, 29–39.
[CrossRef] [PubMed]
25. Koletzko, B.; Schmidt, E.; Bremer, H.J.; Haug, M.; Harzer, G. Effects of dietary long-chain polyunsaturated
fatty acids on the essential fatty acid status of premature infants. Eur. J. Pediatr. 1989, 148, 669–675.
[CrossRef] [PubMed]
26. Hsieh, A.T.; Brenna, J.T. Dietary docosahexaenoic acid but not arachidonic acid influences central nervous
system fatty acid status in baboon neonates. Prostaglandins Leukot. Essent. Fat. Acids 2009, 81, 105–110.
[CrossRef] [PubMed]
27. Farquharson, J.; Cockburn, F.; Patrick, W.A.; Jamieson, E.C.; Logan, R.W. Infant cerebral cortex
phospholipid fatty-acid composition and diet. Lancet 1992, 340, 810–813. [CrossRef]
28. Makrides, M.; Neumann, M.A.; Byard, R.W.; Simmer, K.; Gibson, R.A. Fatty acid composition of brain,
retina, and erythrocytes in breast- and formula-fed infants. Am. J. Clin. Nutr. 1994, 60, 189–194. [PubMed]
29. Harsløf, L.B.S.; Larsen, L.H.; Ritz, C.; Hellgren, L.I.; Michaelsen, K.F.; Vogel, U.; Lauritzen, L. FADS
genotype and diet are important determinants of DHA status: A cross-sectional study in Danish infants.
Am. J. Clin. Nutr. 2013, 97, 1403–1410. [CrossRef] [PubMed]
30. Lauritzen, L.; Carlson, S.E. Maternal fatty acid status during pregnancy and lactation and relation to
newborn and infant status. Mater. Child Nutr. 2011, 7, 41–58. [CrossRef] [PubMed]
31. Rise, P.; Tragni, E.; Ghezzi, S.; Agostoni, C.; Marangoni, F.; Poli, A.; Catapano, A.L.; Siani, A.; Iacoviello, L.;
Galli, C. Different patterns characterize omega-6 and omega-3 long chain polyunsaturated fatty acid levels
in blood from Italian infants, children, adults and elderly. Prostaglandins Leukot. Essent. Fat. Acids 2013, 89,
215–220. [CrossRef] [PubMed]
32. Rahmawaty, S.; Charlton, K.; Lyons-Wall, P.; Meyer, B.J. Dietary intake and food sources of EPA, DPA and
DHA in Australian children. Lipids 2013, 48, 869–877. [CrossRef] [PubMed]
33. Wolters, M.; Schlenz, H.; Foraita, R.; Galli, C.; Rise, P.; Moreno, L.A.; Molnar, D.; Russo, P.; Veidebaum, T.;
Tornaritis, M.; et al. Reference values of whole-blood fatty acids by age and gender from European children
aged 3–8 years. Int. J. Obes. 2014, 38, S86–S98. [CrossRef] [PubMed]
34. Crawford, M.A.; Hassam, G.A.; Williams, G.; Whitehouse, W.L. Essential fatty acids and fetal brain growth.
Lancet 1976, 1, 452–453. [CrossRef]
35. Sauerwald, T.U.; Hachey, D.L.; Jensen, C.L.; Chen, H.; Anderson, R.E.; Heird, W.C. Intermediates in
endogenous synthesis of C22:6 omega-3 and C20:4 omega-6 by term and preterm infants. Pediatr. Res.
1997, 41, 183–187. [CrossRef] [PubMed]
36. Salem, N., Jr.; Wegher, B.; Mena, P.; Uauy, R. Arachidonic and docosahexaenoic acids are biosynthesized
from their 18-carbon precursors in human infants. Proc. Natl. Acad. Sci. USA 1996, 93, 49–54. [CrossRef]
[PubMed]
37. Szitanyi, P.; Koletzko, B.; Mydlilova, A.; Demmelmair, H. Metabolism of C-13-labeled linoleic acid in
newborn infants during the first week of life. Pediatr. Res. 1999, 45, 669–673. [CrossRef] [PubMed]
38. Uauy, R.D.; Mena, P.; Wegher, B.; Nieto, S.; Salem, N., Jr. Long chain polyunsaturated fatty acid formation
in neonates: Effect of gestational age and intrauterine growth. Pediatr. Res. 2000, 47, 127–135. [CrossRef]
[PubMed]
Nutrients 2016, 8, 6 13 of 17
39. Carnielli, V.P.; Simonato, M.; Verlato, G.; Luijendijk, I.; de Curtis, M.; Sauer, P.J.; Cogo, P.E. Synthesis of
long-chain polyunsaturated fatty acids in preterm newborns fed formula with long-chain polyunsaturated
fatty acids. Am. J. Clin. Nutr. 2007, 86, 1323–1330. [PubMed]
40. Lin, Y.H.; Llanos, A.; Mena, P.; Uauy, R.; Salem, N., Jr.; Pawlosky, R.J. Compartmental analyses of
H-2(5)-alpha-linolenic acid and C-13-U-eicosapentaenoic acid toward synthesis of plasma labeled 22:6 n-3
in newborn term infants. Am. J. Clin. Nutr. 2010, 92, 284–293. [CrossRef] [PubMed]
41. Xie, L.; Innis, S.M. Genetic Variants of the FADS1 FADS2 gene cluster are associated with altered n-6 and n-3
essential fatty acids in plasma and erythrocyte phospholipids in women during pregnancy and in breast
milk during lactation. J. Nutr. 2008, 138, 2222–2228. [CrossRef] [PubMed]
42. Koletzko, B.; Lattka, E.; Zeilinger, S.; Illig, T.; Steer, C. Genetic variants of the fatty acid desaturase
gene cluster predict amounts of red blood cell docosahexaenoic and other polyunsaturated fatty acids in
pregnant women: Findings from the Avon Longitudinal Study of Parents and Children. Am. J. Clin. Nutr.
2011, 93, 211–219. [CrossRef] [PubMed]
43. Schaeffer, L.; Gohlke, H.; Muller, M.; Heid, I.M.; Palmer, L.J.; Kompauer, I.; Demmelmair, H.; Illig, T.;
Koletzko, B.; Heinrich, J. Common genetic variants of the FADS1 FADS2 gene cluster and their
reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum. Mol. Genet.
2006, 15, 1745–1756. [CrossRef] [PubMed]
44. Mathias, R.A.; Vergara, C.; Gao, L.; Rafaels, N.; Hand, T.; Campbell, M.; Bickel, C.; Ivester, P.; Sergeant, S.;
Barnes, K.C.; et al. FADS genetic variants and omega-6 polyunsaturated fatty acid metabolism in a
homogeneous island population. J. Lipid Res. 2010, 51, 2766–2774. [CrossRef] [PubMed]
45. Bokor, S.; Dumont, J.; Spinneker, A.; Gonzalez-Gross, M.; Nova, E.; Widhalm, K.; Moschonis, G.; Stehle, P.;
Amouyel, P.; de Henauw, S.; et al. Single nucleotide polymorphisms in the FADS gene cluster are associated
with delta-5 and delta-6 desaturase activities estimated by serum fatty acid ratios. J. Lipid Res. 2010, 51,
2325–2333. [CrossRef] [PubMed]
46. Morales, E.; Bustamante, M.; Gonzalez, J.R.; Guxens, M.; Torrent, M.; Mendez, M.; Garcia-Esteban, R.;
Julvez, J.; Forns, J.; Vrijheid, M.; et al. Genetic variants of the FADS gene cluster and ELOVL gene family,
colostrum LCPUFA levels, breastfeeding, and child cognition. PLoS ONE 2011, 6, e17181. [CrossRef]
[PubMed]
47. Moltó-Puigmartí, C.; Plat, J.; Mensink, R.P.; Müller, A.; Jansen, E.; Zeegers, M.P.; Thijs, C. FADS1 FADS2
gene variants modify the association between fish intake and the docosahexaenoic acid proportions in
human milk. Am. J. Clin. Nutr. 2010, 91, 1368–1376. [CrossRef] [PubMed]
48. Lattka, E.; Rzehak, P.; Szabo, E.; Jakobik, V.; Weck, M.; Weyermann, M.; Grallert, H.; Rothenbacher, D.;
Heinrich, J.; Brenner, H.; et al. Genetic variants in the FADS gene cluster are associated with arachidonic
acid concentrations of human breast milk at 1.5 and 6 mo postpartum and influence the course of milk
dodecanoic, tetracosenoic, and trans-9-octadecenoic acid concentrations over the duration of lactation.
Am. J. Clin. Nutr. 2011, 93, 382–391. [PubMed]
49. Steer, C.D.; Hibbeln, J.R.; Golding, J.; Smith, G.D. Polyunsaturated fatty acid levels in blood during
pregnancy, at birth and at 7 years: Their associations with two common FADS2 polymorphisms.
Hum. Mol. Genet. 2012, 21, 1504–1512. [CrossRef] [PubMed]
50. Lattka, E.; Koletzko, B.; Zeilinger, S.; Hibbeln, J.R.; Klopp, N.; Ring, S.M.; Steer, C.D. Umbilical cord
PUFA are determined by maternal and child fatty acid desaturase (FADS) genetic variants in the Avon
Longitudinal Study of Parents and Children (ALSPAC). Br. J. Nutr. 2013, 109, 1196–1210. [CrossRef]
[PubMed]
51. Jensen, H.A.R.; Harsløf, L.B.S.; Nielsen, M.S.; Christensen, L.B.; Ritz, C.; Michaelsen, K.F.; Vogel, U.;
Lauritzen, L. FADS single-nucleotide polymorphisms are associated with behavioral outcomes in children,
and the effect varies between genders and is dependent on PPAR genotype. Am. J. Clin. Nutr. 2014, 100,
826–832. [CrossRef] [PubMed]
52. Glaser, C.; Rzehak, P.; Demmelmair, H.; Klopp, N.; Heinrich, J.; Koletzko, B. LISA study group. Influence of
FADS polymorphisms on tracking of serum glycerophospholipid fatty acid concentrations and percentage
composition in children. PLoS ONE 2011, 6, e21933. [CrossRef] [PubMed]
53. European Food Safety Authority. The Panel on Dietetic Products, Nutrition and Allergies on a request from
Mead Johnson Nutritionals. Scientific opinion on DHA and ARA and visual development. EFSA J. 2009,
941, 1–14. [CrossRef]
Nutrients 2016, 8, 6 14 of 17
54. Uauy, R.; Hoffman, D.R.; Mena, P.; Llanos, A.; Birch, E.E. Term infant studies of DHA and ARA
supplementation on neurodevelopment: Results of randomized controlled trials. J. Pediatr. 2003, 143,
S17–S25. [CrossRef]
55. Simmer, K.; Patole, S.K.; Rao, S.C. Long-chain polyunsaturated fatty acid supplementation in infants born
at term. Cochrane Database Syst. Rev. 2011, 12. [CrossRef]
56. Qawasmi, A.; Landeros-Weisenberger, A.; Leckman, J.F.; Bloch, M.H. Meta-analysis of long-chain
polyunsaturated fatty acid supplementation of formula and infant cognition. Pediatrics 2012, 129,
1141–1149. [CrossRef] [PubMed]
57. Schulzke, S.M.; Patole, S.K.; Simmer, K. Long-chain polyunsaturated fatty acid supplementation in preterm
infants. Cochrane Database Syst. Rev. 2011, 2. [CrossRef]
58. Delgado-Noguera, M.F.; Calvache, J.A.; Cosp, X.B. Supplementation with long chain polyunsaturated fatty
acids (LCPUFA) to breastfeeding mothers for improving child growth and development. Cochrane Database
Syst. Rev. 2010, 12. [CrossRef]
59. Gould, J.F.; Smithers, L.G.; Makrides, M. The effect of maternal omega-3 LCPUFA supplementation during
pregnancy on early childhood cognitive and visual development: A systematic review and meta-analysis
of randomized controlled trials. Am. J. Clin. Nutr. 2013, 97, 531–544. [CrossRef] [PubMed]
60. Makrides, M.; Gibson, R.A.; McPhee, A.J.; Collins, C.T.; Davis, P.G.; Doyle, L.W.; Simmer, K.; Colditz, P.B.;
Morris, S.; Smithers, L.G.; et al. Neurodevelopmental outcomes of preterm infants fed high-dose
docosahexaenoic acid: A randomized controlled trial. JAMA 2009, 301, 175–178. [CrossRef] [PubMed]
61. Makrides, M.; Gibson, R.A.; McPhee, A.J. Effect of DHA supplementation during pregnancy on maternal
depression and neurodevelopment of young children: A randomized controlled trial. JAMA 2010, 304,
1675–1683. [CrossRef] [PubMed]
62. Lauritzen, L.; Jørgensen, M.H.; Olsen, S.F.; Straarup, E.M.; Michaelsen, K.F. Maternal fish oil
supplementation in lactation: Effect on developmental outcome in breast-fed infants. Reprod. Nutr. Dev.
2005, 45, 535–547. [CrossRef] [PubMed]
63. Cheatham, C.L.; Nerhammer, A.S.; Asserhøj, M.; Michaelsen, K.F.; Lauritzen, L. Fish oil supplementation
during lactation: Effects on cognition and behavior at 7 years of age. Lipids 2011, 46, 637–645. [CrossRef]
[PubMed]
64. Asserhøj, M.; Nehammer, S.; Matthiessen, J.; Michaelsen, K.F.; Lauritzen, L. Maternal fish oil
supplementation during lactation may adversely affect long-term blood pressure, energy intake, and
physical activity of 7-year-old boys. J. Nutr. 2009, 139, 298–304. [CrossRef] [PubMed]
65. Steer, C.D.; Smith, G.D.; Emmett, P.M.; Hibbeln, J.R.; Golding, J. FADS2 polymorphisms modify the effect
of breastfeeding on child IQ. PLoS ONE 2010, 5. [CrossRef] [PubMed]
66. Caspi, A.; Williams, B.; Kim-Cohen, J.; Craig, I.W.; Milne, B.J.; Poulton, R.; Schalkwyk, L.C.; Taylor, A.;
Werts, H.; Moffitt, T.E. Moderation of breastfeeding effects on the IQ by genetic variation in fatty acid
metabolism. Proc. Natl. Acad. Sci. USA 2007, 104, 18860–18865. [CrossRef] [PubMed]
67. Groen-Blokhuis, M.M.; Franic, S.; van Beijsterveldt, C.E.M.; de Geus, E.; Bartels, M.; Davies, G.E.; Ehli, E.A.;
Xiao, X.J.; Scheet, P.A.; Althoff, R.; et al. A prospective study of the effects of breastfeeding and FADS2
polymorphisms on cognition and hyperactivity/attention problems. Am. J. Med. Genet. B. Neuropsychiatr.
Genet. 2013, 162, 457–465. [CrossRef] [PubMed]
68. Martin, N.W.; Benyamin, B.; Hansell, N.K.; Montgomery, G.W.; Martin, N.G.; Wright, M.J.; Bates, T.C.
Cognitive function in adolescence: Testing for interactions between breast-feeding and FADS2
polymorphisms. J. Am. Acad. Child Adolesc. Psychiatry 2011, 50, 55–62. [CrossRef] [PubMed]
69. Steer, C.D.; Lattka, E.; Koletzko, B.; Golding, J.; Hibbeln, J.R. Maternal fatty acids in pregnancy, FADS
polymorphisms, and child intelligence quotient at 8 y of age. Am. J. Clin. Nutr. 2013, 98, 1575–1582.
[CrossRef] [PubMed]
70. Browning, L.M.; Walker, C.G.; Mander, A.P.; West, A.L.; Madden, J.; Gambell, J.M.; Young, S.; Wang, L.;
Jebb, S.A.; Calder, P.C. Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when
given as supplements providing doses equivalent to typical intakes of oily fish. Am. J. Clin. Nutr. 2012, 96,
748–758. [CrossRef] [PubMed]
71. Drover, J.; Hoffman, D.R.; Castaneda, Y.S.; Morale, S.E.; Birch, E.E. Three randomized controlled
trials of early long-chain polyunsaturated fatty acid supplementation on means-end problem solving in
9-month-olds. Child Dev. 2009, 80, 1376–1384. [CrossRef] [PubMed]
Nutrients 2016, 8, 6 15 of 17
72. Hoffman, D.R.; Theuer, R.C.; Castaneda, Y.S.; Wheaton, D.H.; Bosworth, R.G.; O’Connor, A.R.; Morale, S.E.;
Wiedemann, L.E.; Birch, E.E. Maturation of visual acuity is accelerated in breast-fed term infants fed baby
food containing DHA-enriched egg yolk. J. Nutr. 2004, 134, 2307–2313. [PubMed]
73. Harbild, H.L.; Harsløf, L.B.S.; Christensen, J.H.; Kannass, K.N.; Lauritzen, L. Fish oil-supplementation from
9 to 12 months of age affects infant attention in a free-play test and is related to change in blood pressure.
Prostaglandins Leukot. Essent. Fat. Acids 2013, 89, 327–333. [CrossRef] [PubMed]
74. Parletta, N.; Cooper, P.; Gent, D.N.; Petkov, J.; O’Dea, K. Effects of fish oil supplementation on learning and
behaviour of children from Australian Indigenous remote community schools: A randomised controlled
trial. Prostaglandins Leukot. Essent. Fat. Acids 2013, 89, 71–79. [CrossRef] [PubMed]
75. Baumgartner, J.; Smuts, C.M.; Malan, L.; Kvalsvig, J.; van Stuijvenberg, M.E.; Hurrell, R.F.;
Zimmermann, M.B. Effects of iron and n-3 fatty acid supplementation, alone and in combination, on
cognition in school children: A randomized, double-blind, placebo-controlled intervention in South Africa.
Am. J. Clin. Nutr. 2012, 96, 1327–1338. [CrossRef] [PubMed]
76. McNamara, R.K.; Able, J.; Jandacek, R.; Rider, T.; Tso, P.; Eliassen, J.C.; Alfieri, D.; Weber, W.; Jarvis, K.;
DelBello, M.P.; et al. Docosahexaenoic acid supplementation increases prefrontal cortex activation during
sustained attention in healthy boys: A placebo-controlled, dose-ranging, functional magnetic resonance
imaging study. Am. J. Clin. Nutr. 2010, 91, 1060–1067. [CrossRef] [PubMed]
77. Sørensen, L.B.; Dyssegaard, C.B.; Damsgaard, C.T.; Petersen, R.A.; Dalskov, S.M.; Hjorth, M.F.;
Andersen, R.; Tetens, I.; Ritz, C.; Astrup, A.; et al. The effect of Nordic school meals on concentration
and school performance in 8 to 11 year-old children in the OPUS School Meal Study: A cluster-randomized
controlled cross-over trial. Br. J. Nutr. 2015, 113, 1280–1291. [CrossRef] [PubMed]
78. Eilander, A.; Hundscheid, D.C.; Osendarp, S.J.; Transler, C.; Zock, P.L. Effects of n-3 long chain
polyunsaturated fatty acid supplementation on visual and cognitive development throughout childhood:
A review of human studies. Prostaglandins Leukot. Essent. Fat. Acids 2007, 76, 189–203. [CrossRef] [PubMed]
79. Osendarp, S.J.M.; Baghurst, K.I.; Bryan, J.; Calvaresi, E.; Hughes, D.; Hussaini, M.; Karyadi, S.J.M.;
van Klinken, B.J.W.; van der Knaap, H.C.M.; Lukito, W.; et al. Effect of a 12-mo micronutrient intervention
on learning and memory in well-nourished and marginally nourished school-aged children: 2 parallel,
randomized, placebo-controlled studies in Australia and Indonesia. Am. J. Clin. Nutr. 2007, 86, 1082–1093.
[PubMed]
80. Kennedy, D.O.; Jackson, P.A.; Elliott, J.M.; Scholey, A.B.; Robertson, B.C.; Greer, J.; Tiplady, B.; Buchanan, T.;
Haskell, C.F. Cognitive and mood effects of 8 weeks’ supplementation with 400 mg or 1000 mg of
the omega-3 essential fatty acid docosahexaenoic acid (DHA) in healthy children aged 10–12 years.
Nutr. Neurosci. 2009, 12, 48–56. [CrossRef] [PubMed]
81. Kirby, A.; Woodward, A.; Jackson, S.; Wang, Y.; Crawford, M.A. A double-blind, placebo-controlled study
investigating the effects of omega-3 supplementation in children aged 8–10 years from a mainstream school
population. Res. Dev. Disabil. 2010, 31, 718–730. [CrossRef] [PubMed]
82. Smuts, C.M.; Greeff, J.; Kvalsvig, J.; Zimmermann, M.; Baumgartner, J. Long-chain n-3 polyunsaturated
fatty acid supplementation decrease physical activity during class in iron deficient South African school
children. Br. J. Nutr. 2015, 113, 212–224. [CrossRef] [PubMed]
83. Rytter, M.J.H.; Andersen, L.B.B.; Houmann, T.; Bilenberg, N.; Hvolby, A.; Mølgaard, C.; Michaelsen, K.F.;
Lauritzen, L. Diet in the treatment of ADHD in children-A systematic review of the literature.
Nord. J. Psychiatry 2015, 69, 1–18. [CrossRef] [PubMed]
84. Brookes, K.J.; Chen, W.; Xu, X.; Taylor, E.; Asherson, P. Association of fatty acid desaturase genes with
attention-deficit/hyperactivity disorder. Biol. Psychiatry 2006, 60, 1053–1061. [CrossRef] [PubMed]
85. Harsløf, L.B.; Damsgaard, C.; Hellgren, L.; Andersen, A.; Vogel, U.; Lauritzen, L. Effects on metabolic
markers are modified by PPARG2 and COX2 polymorphisms in infants randomized to fish oil. Genes Nutr.
2014, 9, 1–11. [CrossRef] [PubMed]
86. Damsgaard, C.T.; Schack-Nielsen, L.; Michaelsen, K.F.; Fruekilde, M.B.; Hels, O.; Lauritzen, L. Fish oil
affects blood pressure and the plasma lipid profile in healthy Danish infants. J. Nutr. 2006, 136, 94–99.
[PubMed]
87. Damsbo-Svendsen, S.; Rønsholdt, M.D.; Lauritzen, L. Fish oil-supplementation increases appetite in
healthy adults. A randomized controlled cross-over trial. Appetite 2013, 66, 62–66. [CrossRef] [PubMed]
Nutrients 2016, 8, 6 16 of 17
88. Stonehouse, W.; Conlon, C.A.; Podd, J.; Hill, S.R.; Minihane, A.M.; Haskell, C.; Kennedy, D.
DHA supplementation improved both memory and reaction time in healthy young adults: A randomized
controlled trial. Am. J. Clin. Nutr. 2013, 97, 1134–1143. [CrossRef] [PubMed]
89. Agostoni, C.; Zuccotti, G.V.; Radaelli, G.; Besana, R.; Podesta, A.; Sterpa, A.; Rottoli, A.; Riva, E.;
Giovannini, M. Docosahexaenoic acid supplementation and time at achievement of gross motor milestones
in healthy infants: A randomized, prospective, double-blind, placebo-controlled trial. Am. J. Clin. Nutr.
2009, 89, 64–70. [CrossRef] [PubMed]
90. Yurko-Mauro, K.; Alexander, D.D.; van Elswyk, M.E. Docosahexaenoic acid and adult memory: A
systematic review and meta-analysis. PLoS ONE 2015, 10. [CrossRef]
91. Morris, M.C.; Evans, D.A.; Tangney, C.C.; Bienias, J.L.; Wilson, R.S. Fish consumption and cognitive decline
with age in a large community study. Arch. Neurol. 2005, 62, 1849–1853. [CrossRef] [PubMed]
92. Lim, W.S.; Gammack, J.K.; van Niekerk, J.; Dangour, A.D. Omega-3 fatty acid for the prevention of
dementia. Cochrane Database Syst. Rev. 2006, 1. [CrossRef]
93. Chiu, C.C.; Su, K.P.; Cheng, T.C.; Liu, H.C.; Chang, C.J.; Dewey, M.E.; Stewart, R.; Huang, S.Y. The effects
of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: A preliminary
randomized double-blind placebo-controlled study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32,
1538–1544. [CrossRef] [PubMed]
94. Yurko-Mauro, K.; McCarthy, D.; Rom, D.; Nelson, E.B.; Ryan, A.S.; Blackwell, A.; Salem, N., Jr.; Stedman, M.
Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement.
2010, 6, 456–464. [CrossRef] [PubMed]
95. Astarita, G.; Jung, K.M.; Berchtold, N.C.; Nguyen, V.Q.; Gillen, D.L.; Head, E.; Cotman, C.W.; Piomelli, D.
Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer’s
disease. PLoS ONE 2010, 5, e12538. [CrossRef] [PubMed]
96. Bazan, N.G.; Molina, M.F.; Gordon, W.C. Docosahexaenoic acid Signal lipidomics in nutrition: Significance
in aging, neuroinflammation, macular degeneration, Alzheimer’s, and other neurodegenerative diseases.
Annu. Rev. Nutr. 2011, 31, 321–351. [CrossRef] [PubMed]
97. De Mel, D.; Suphioglu, C. Fishy business: Effect of omega-3 fatty acids on zinc transporters and free zinc
availability in human neuronal cells. Nutrients 2014, 6, 3245–3258. [CrossRef] [PubMed]
98. Labrousse, V.F.; Nadjar, A.; Joffre, C.; Costes, L.; Aubert, A.; Gregoire, S.; Bretillon, L.; Laye, S. Short-term
long chain omega3 diet protects from neuroinflammatory processes and memory impairment in aged mice.
PLoS ONE 2012, 7, e36861. [CrossRef] [PubMed]
99. Sands, S.A.; Windsor, S.L.; Reid, K.J.; Harris, W.S. The impact of age, body mass index, and fish intake on
the EPA and DHA content of human erythrocytes. Lipids 2005, 40, 343–347. [CrossRef] [PubMed]
100. Hoen, W.P.; Lijmer, J.G.; Duran, M.; Wanders, R.J.; van Beveren, N.J.; de Haan, L. Red blood cell
polyunsaturated fatty acids measured in red blood cells and schizophrenia: A meta-analysis. Psychiatry Res.
2013, 207, 1–12. [CrossRef] [PubMed]
101. Peet, M.; Shah, S.; Selvam, K.; Ramchand, C.N. Polyunsaturated fatty acid levels in red cell membranes of
unmedicated schizophrenic patients. World J. Biol. Psychiatry 2004, 5, 92–99. [CrossRef] [PubMed]
102. Khan, M.M.; Evans, D.R.; Gunna, V.; Scheffer, R.E.; Parikh, V.V.; Mahadik, S.P. Reduced erythrocyte
membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated
first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 2002, 58, 1–10.
[CrossRef]
103. Reyazuddin, M.; Azmi, S.A.; Islam, N.; Rizvi, A. Oxidative stress and level of antioxidant enzymes in
drug-naive schizophrenics. Indian J. Psychiatry 2014, 56, 344–349. [PubMed]
104. Hashimoto, M.; Maekawa, M.; Katakura, M.; Hamazaki, K.; Matsuoka, Y. Possibility of polyunsaturated
fatty acids for the prevention and treatment of neuropsychiatric illnesses. J. Pharmacol. Sci. 2014, 124,
294–300. [CrossRef] [PubMed]
105. Amminger, G.P.; Schafer, M.R.; Papageorgiou, K.; Klier, C.M.; Cotton, S.M.; Harrigan, S.M.; Mackinnon, A.;
McGorry, P.D.; Berger, G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders:
A randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67, 146–154. [CrossRef] [PubMed]
106. Machado-Vieira, R.; Mallinger, A.G. Abnormal function of monoamine oxidase-A in comorbid major
depressive disorder and cardiovascular disease: Pathophysiological and therapeutic implications.
Mol. Med. Rep. 2012, 6, 915–922. [CrossRef] [PubMed]
Nutrients 2016, 8, 6 17 of 17
107. Weissman, M.M.; Bland, R.C.; Canino, G.J.; Faravelli, C.; Greenwald, S.; Hwu, H.G.; Joyce, P.R.; Karam, E.G.;
Lee, C.K.; Lellouch, J.; et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA
1996, 276, 293–299. [CrossRef] [PubMed]
108. Severus, W.E.; Littman, A.B.; Stoll, A.L. Omega-3 fatty acids, homocysteine, and the increased risk of
cardiovascular mortality in major depressive disorder. Harv. Rev. Psychiatry 2001, 9, 280–293. [CrossRef]
[PubMed]
109. Huang, T.; Zheng, J.; Chen, Y.; Yang, B.; Wahlqvist, M.L.; Li, D. High consumption of
omega-3 polyunsaturated fatty acids decrease plasma homocysteine: A meta-analysis of randomized,
placebo-controlled trials. Nutrition 2011, 27, 863–867. [CrossRef] [PubMed]
110. Bourre, J.M. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages
and during ageing. J. Nutr. Health Aging 2004, 8, 163–174. [PubMed]
111. Assies, J.; Mocking, R.J.T.; Lok, A.; Ruhé, H.G.; Pouwer, F.; Schene, A.H. Effects of oxidative stress
on fatty acid- and one-carbon- metabolism in psychiatric and cardiovascular disease comorbidity.
Acta Psychiatr. Scand. 2014, 130, 163–180. [CrossRef] [PubMed]
112. Lin, P.Y.; Huang, S.Y.; Su, K.P. A meta-analytic review of polyunsaturated fatty acid compositions in patients
with depression. Biol. Psychiatry 2010, 68, 140–147. [CrossRef] [PubMed]
113. McNamara, R.K.; Vannest, J.J.; Valentine, J.C. Role of perinatal long-chain omega-3 fatty acids in cortical
circuit maturation: Mechanisms and implications for psychopathology. World J. Psychiatry 2015, 5, 15–34.
[PubMed]
114. European Food Safety Authority. The Panel on Dietetic Products, Nutrition and Allergies on a request from
Mead Johnson Nutritionals. Scientific Opinion on DHA and ARA and brain development. EFSA J. 2009,
1000, 1–13. [CrossRef]
115. European Food Safety Authority. The Panel on Dietetic Products, Nutrition and Allergies. Scientific
Opinion on the substantiation of a health claim related to DHA and contribution to normal brain
development pursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA J. 1924, 12. [CrossRef]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open
access article distributed under the terms and conditions of the Creative Commons by
Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
